In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...

Last year, DeepMind’s AlphaFold2 AI system made a “significant contribution to humanity’s understanding of biology.” Alphabet has now taken that advancement and created a new company called Isomorphic ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design and ...

Last year, DeepMind produced a stunning advance in scientific research, demonstrating how its artificial intelligence could be used to predict 3D structures of unique proteins in a solution to a ...

The company will build off of breakthroughs in protein prediction from DeepMind and inches Big Tech one step further into the healthcare industry. Reading time 2 minutes Alphabet has spun off a new ...

The field of drug discovery has been supercharged by the capabilities of AI, which several companies have applied in various ways to turn an enormous practical problem into a tractable information ...

A new Alphabet company will use artificial intelligence methods for drug discovery, Google’s parent company announced Thursday. It’ll build off of the work done by DeepMind, another Alphabet ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...